explore -WSS

explore

author：focus 2025-08-25 07:30:17 - browse：82

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： RaDonda Vaught case: a double standard for nurses, physicians

WSS

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Connecting traumatic brain injury and domestic violence

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Grail is spending more than ever lobbying Congress

Can food be medicine? And other questions about a new push

Listen: PBM conflicts, RSV vaccines, & the future of flu season

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Wikipedia

The high cost of giving birth even with insurance

Medicare Advantage 2025 payments will dip, Biden administration says

Guidelines to prevent youth baseball injuries need more muscle

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Novavax promises a turnaround & Lilly roils the obesity market

Did the public have the right to know Arthur Ashe had AIDS?

Moonlake's readout produced a cash windfall. Risks remain

Mass General Brigham physicians react to latest merger step

Bright Health sells Medicare Advantage business to Molina

Mass General Brigham physicians react to latest merger step

leisure time

Researchers test human milk's ability to repair gut microbiome

Gut bacteria may contribute to kidney autoimmunity, study finds

Hundreds died while taking an arthritis drug, but nobody alerted patients

Option Care buys Amedisys in $3.6 billion home care deal

New case study details death in closely watched Alzhiemer's trial

Option Care buys Amedisys in $3.6 billion home care deal

entertainment

hotspot

explore

knowledge